1. Home
  2. GNPX vs BKYI Comparison

GNPX vs BKYI Comparison

Compare GNPX & BKYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

N/A

Current Price

$2.00

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Logo BIO-key International Inc.

BKYI

BIO-key International Inc.

N/A

Current Price

$0.65

Market Cap

7.1M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
GNPX
BKYI
Founded
2009
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
7.1M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
GNPX
BKYI
Price
$2.00
$0.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
852.6K
248.8K
Earning Date
01-01-0001
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
76.33
N/A
EPS
N/A
N/A
Revenue
N/A
$6,302,984.00
Revenue This Year
N/A
$7.45
Revenue Next Year
N/A
$23.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
111.81
52 Week Low
$0.14
$0.51
52 Week High
$12.97
$1.97

Technical Indicators

Market Signals
Indicator
GNPX
BKYI
Relative Strength Index (RSI) 46.07 50.08
Support Level $1.90 $0.62
Resistance Level $2.51 $0.86
Average True Range (ATR) 0.20 0.06
MACD 0.01 0.00
Stochastic Oscillator 32.89 48.16

Price Performance

Historical Comparison
GNPX
BKYI

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About BKYI BIO-key International Inc.

BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.

Share on Social Networks: